519 related articles for article (PubMed ID: 16204008)
21. Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
Chin LT; Chu C; Chen HM; Wang DW; Liao SK
Chang Gung Med J; 2008; 31(1):1-15. PubMed ID: 18419049
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy for melanoma: how can tolerance be overcome?].
Robert C
Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
[No Abstract] [Full Text] [Related]
23. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
25. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
Weber JS
Melanoma Res; 2006 Oct; 16(5):379-83. PubMed ID: 17013086
[TBL] [Abstract][Full Text] [Related]
26. The anti-idiotype vaccines for immunotherapy.
Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of melanoma.
Rietschel P; Chapman PB
Hematol Oncol Clin North Am; 2006 Jun; 20(3):751-66. PubMed ID: 16762733
[TBL] [Abstract][Full Text] [Related]
28. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
29. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients.
Weber JS
Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797
[No Abstract] [Full Text] [Related]
30. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Robinson MR; Chan CC; Yang JC; Rubin BI; Gracia GJ; Sen HN; Csaky KG; Rosenberg SA
J Immunother; 2004; 27(6):478-9. PubMed ID: 15534492
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
Finn OJ
Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
[No Abstract] [Full Text] [Related]
32. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
33. Serotherapy of cancer.
Harris DT; Mastrangelo MJ
Semin Oncol; 1989 Jun; 16(3):180-98. PubMed ID: 2658082
[No Abstract] [Full Text] [Related]
34. [Monoclonal antibody therapy: a literature review].
Del Debbio CB; Tonon LM; Secoli SR
Rev Gaucha Enferm; 2007 Mar; 28(1):133-42. PubMed ID: 17658067
[TBL] [Abstract][Full Text] [Related]
35. Technology evaluation: edrecolomab, Centocor Inc.
Abicht A; Lochmüller H
Curr Opin Mol Ther; 2000 Oct; 2(5):593-600. PubMed ID: 11249762
[TBL] [Abstract][Full Text] [Related]
36. Translational research in melanoma.
Tsai S; Sabel MS
Surg Oncol Clin N Am; 2008 Apr; 17(2):391-419, ix-x. PubMed ID: 18375359
[TBL] [Abstract][Full Text] [Related]
37. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
38. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
39. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
40. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
Agarwala SS; Ribas A
J Immunother; 2010; 33(6):557-69. PubMed ID: 20551840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
